NRC FORM 374 U.S. NUCLEAR REGULAT	ORY COMMISSION PAGEOFPAGES Amendment No. 39			
MATERIALS L				
Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10. Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deerned to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.				
902120	216005			
Licensee	In accordance with letter received February 9, 2007,			
1. Porter Valparaiso Hospital Campus	3. License number 13-17073-01 is amended			
	in its entirety to read as follows:			
2. 814 LaPorte Avenue	4. Expiration date November 30, 2013			
Valparaiso, IN 46383-5898	5. Docket No. 030-12150 Reference No.			
<ul> <li>6. Byproduct, source, and/or special nuclear material</li> <li>A. Any byproduct material permitted by 10 CFR 35.100</li> <li>B. Any byproduct material permitted by 10 CFR 85.200</li> <li>C. Any byproduct material permitted by 10 CFR 85.300</li> <li>D. Any byproduct material permitted by 10 CFR 85.300</li> <li>D. Any byproduct material permitted by 10 CFR 85.400</li> <li>G. Any byproduct material permitted by 10 CFR 85.400</li> <li>G. Any byproduct material permitted by 10 CFR 85.400</li> <li>G. Any byproduct material permitted by 10 CFR 85.400</li> <li>G. Any byproduct material permitted by 10 CFR 85.400</li> <li>G. Any byproduct material permitted by 10 CFR 85.400</li> <li>G. Any byproduct material permitted by 10 CFR 85.400</li> <li>G. Any byproduct material permitted by 10 CFR 85.400</li> <li>G. Any byproduct material permitted by 10 CFR 85.400</li> <li>G. Any uptake, dilution and excretion stude permitted by 10 CFR 35.100.</li> <li>B. Any imaging and localization study permitted by 10 CFR 35.200.</li> </ul>				
C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.				
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.				
CONDITIONS				
<ol> <li>Licensed material shall be used only at the licensee's facilities located at 814 LaPorte Avenue, Valparaiso, Indiana.</li> </ol>				

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION		PAGE 2 of 3 PAGES				
				License Number 13-17073-01		
MATERIALS LICENSE SUPPLEMENTARY SHEET		Docket or Reference Number 030-12150				
				Amendment No. 39		
			<u></u>	L		
<b>11.</b> A.	The Ra	idiation Safety Officer for this licens	e is James	M. Forde, M.D.		
В.	The Ra	The Radiation Safety Officer for brachytherapy only is Apparao Devata, Ph.D.				
12. Lic	ensed m	aterial is only authorized for use by	, or under ti	he supervision of:		
А.	A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.					
В.	The fol	The following individuals are authorized users for medical uses:				
	Author	ized Users	R E O	terial and Use		
-	G. Dav	id Beiser, M.D.	10 CFR 35	10035.200  and  35.300.		
	John A	. Forchetti, M.D.	10 CFR 35	5.100 and 35,200.		
	Hector	J. Marchand M.D.	10 CFR 35	5.200 P		
	Richar	d A. Boyd, M.D.	10 CFR 35	f sodium iodide-131 in quantities less		
		A A	than or eq	33 millicuries).		
	William	n R. Kelley, M.D.		<b>35.200</b> and <b>35.300</b> .		
	Anil Ko	othari, M.D.		100, 5.200 an <b>coral administration of</b>		
		T. Mark	Stableu			
	Koppol	lu P. Sarma, M.D. 🎷 🤈 🖉	10 ČFR 35			
	Kamala	a Modur, M.D.	THEFF 85	5.400		
	James	M. Forde, M.D.	10 CFR 35	5.100, 35.200 and 35.300.		
	Jeffrey	M. Huth, M.D.	10 CFR 35	5.100 and 35.200.		
	Maxim	o V. Bleza, D.O.	10 CFR 35	5.100, 35.200 and 35.300.		
	Amjad	Alkadri, M.D.	10 CFR 35	5.100, 35.200 and 35.300.		
	Bobby	Ajay Shah, M.D.	10 CFR 35	5.100, 35.200 and 35.300.		
	Jeffrey	Jon Quackenbush, M.D.	10 CFR 35	i.300, 35.400		
	Michell	e Stevens-Kraut, M.D.	10 CFR 35	5.100, 35.200 and 35.300.		

NRC FORM 374A U.S. NUC	LEAR REGULATORY COMMISSION	PAGE 3 of 3 PAGES		
		License Number 13-17073-01		
MATERIALS LICENSE SUPPLEMENTARY SHEET		Docket or Reference Number 030-12150		
		Amendment No. 39		
		<b>1</b>		
Lorenz H. Schielke, M.D.	10 CFR 35	6,100 and 35.200.		
Yazan Kaakaji, M.D.	10 CFR 35	6.100 and 35.200.		
Esther Lee, M.D.	10 CFR 35 iodine-131	5.100, 35.200 and 35.300 (limited to the use of I).		
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.				
14. The licensee may transport lic "Packaging and Transportatio	ensed material in accordance n of Radio <b>ac</b> ti <b>ve Materia</b> ls	ce with the provisions of 10 CFR Part 71,		
<ul> <li>15. Except as specifically provided otherwise in this license, the license shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, the cense condition does not limit the licensee's ability to make changes the regulations. Additionally, the cense condition does not limit the licensee's ability to make changes the regulations. Additionally, the cense condition does not limit the licensee's ability to make changes the regulations are provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission regulations she there are nuclease the statements, representations, and procedures in the transee's application. Correspondence are more restrictive than the regulations.</li> <li>A. Application dated July 22, 2002, applications are considered in 10 CFR 35.26.</li> <li>B. Letters dated March 2, 2002, application 20, application 10, 2005 and June 3, 2005 (with attached sketch);</li> <li>C. Facsimile letter dated September 22, 2005 (the attached sketches).</li> </ul>				
	FOR THE U.S. NU	JCLEAR REGULATORY COMMISSION		
FEB <b>2 2</b> 2007 Date	By James R. Mulla Materials Licen Region III			